Vaxcyte, Inc. 4

Director John Markels received a stock option award for 23,029 shares of Vaxcyte, Inc. common stock at a $56.04 exercise price.

On July 16, 2026, Vaxcyte, Inc. director John Markels received a stock option award for 23,029 shares of common stock at an exercise price of $56.04 per share. The option vests over 36 months, with one-third vesting on July 16, 2027 and the remaining two-thirds vesting in equal monthly installments thereafter, contingent on his continued service to the company. This award represents a routine equity compensation grant, increasing his derivative holdings and providing potential future ownership of 23,029 shares, with an aggregate option notional value of approximately $1.29 million based on the exercise price.

Filing Facts

CIK

1649094

Ticker

PCVX

Form

4

Source Type

fda

Accession

0001803424-26-000004

Alert Tier

6